Last reviewed · How we verify
topical prostaglandin analogs
Topical prostaglandin analogs, marketed by Maisonneuve-Rosemont Hospital, hold a position in the ophthalmic market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its key patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | topical prostaglandin analogs |
|---|---|
| Sponsor | Maisonneuve-Rosemont Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy
- A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma (PHASE4)
- Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men (PHASE1, PHASE2)
- Evaluation of Retina in Patients With Glaucoma Using Topical Prostaglandins Undergoing Trabeculectomy Surgery (NA)
- Impact of Home Intraocular Pressure Telemonitoring on Intraocular Pressure Control and Glaucoma Progression (NA)
- PSLT Compared to Prostaglandin Analogue Eye Drops (NA)
- Efficacy and Safety of Lens Extraction in Patients With Pseudoexfoliation Glaucoma (NA)
- African Glaucoma Laser Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- topical prostaglandin analogs CI brief — competitive landscape report
- topical prostaglandin analogs updates RSS · CI watch RSS
- Maisonneuve-Rosemont Hospital portfolio CI